TAVR cost-effective compared with SAVR in intermediate risk patients with aortic stenosis

November 1, 2017, Cardiovascular Research Foundation

Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.

Findings were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Researchers led by Dr. David J. Cohen (Saint Luke's Mid America Heart Institute, Kansas City, MO) used data from the PARTNER 2A randomized trial and the SAPIEN-3 Intermediate Risk registry to perform a formal, patient-level economic analysis comparing TAVR using either the SAPIEN XT valve (XT-TAVR) or the SAPIEN-3 valve (S3-TAVR) with SAVR. The comparison between XT-TAVR and SAVR was based upon randomized assignment within PARTNER 2A; the comparison between S3-TAVR and SAVR was not randomized. Procedural costs were assessed based on measured resource utilization and all other costs were assessed by linking trial data with Medicare claims for the index hospitalization and follow-up period or by piecewise regression models for the remaining patients.

PARTNER 2A

In the trial, XT-TAVR led to significant reductions in procedure duration compared with SAVR (102±46 vs. 236±83, P<0.001) and hospital length of stay (6.4±5.5 vs. 10.9±7.6, P<0.001). Although procedural costs were $22,083 higher with XT-TAVR than SAVR (reflecting the higher cost of the transcatheter valve), most of this higher cost was offset by reduced costs related to length of stay and in-hospital complications such that total costs for the index hospitalization were only ~$2,900 higher with TAVR ($61,433 vs. $58,545; P=0.014). Over the following 24 months, follow-up costs were substantially lower with XT-TAVR (by $9,303 per patient) such that total medical care costs were lower with TAVR than SAVR two-year follow-up ($107,716 vs. $114,132, P=0.014). When the trial results were projected over a lifetime horizon, XT-TAVR was projected to result in both cost savings of $7,949 and greater quality adjusted life expectancy (by 0.15 years).

SAPIEN 3

When performance of S3-TAVR in the S3i registry was compared with SAVR within PARTNER 2A, the reductions in procedure duration (84±38 vs. 236±83, P<0.001) and length of stay (4.6±5.7 vs. 10.9±7.6, P<0.001) were even greater than in the randomized trial. As a result, despite the higher cost of the transcatheter , total costs for the index hospitalization were lower with S3-TAVR than SAVR ($54,256 vs. $58,410, P=0.014). Over the first year of follow-up, S3-TAVR resulted in additional cost savings of nearly $11,000/patient. When these in-trial results (including improved survival at two years) were projected over a lifetime horizon, S3 TAVR was projected to yield lifetime cost savings of $9,692 per patient and a significant gain in quality adjusted life-years (0.27 years)—an economically dominant strategy.

"For patients with severe aortic stenosis and intermediate surgical risk similar to those enrolled in the PARTNER 2 trial, these results demonstrating substantial cost savings and improved quality-adjusted life expectancy, indicate that transcatheter should be considered the preferred strategy based on both clinical and economic considerations," said David J. Cohen, MD, MSc, Director of Cardiovascular Research at Saint Luke's Mid America Heart Institute in Kansas City, MO.

The PARTNER 2A and SAPIEN 3 Cost-effectiveness Trial was funded by Edwards Lifesciences. Dr. Cohen reported receiving research grant support from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott Vascular as well as consulting income from Edwards Lifesciences and Medtronic.

Explore further: Results of PARTNER II QUALITY OF LIFE study presented

Related Stories

Results of PARTNER II QUALITY OF LIFE study presented

November 1, 2016
Patients with severe aortic stenosis (AS) at intermediate surgical risk, and who are treated with transcatheter aortic valve replacement (TAVR) had improved health status at one month compared with surgical aortic valve replacement ...

Results of US CoreValve High Risk Trial reported at TCT 2014

September 15, 2014
According to a new study, transcatheter aortic valve replacement (TAVR) provided meaningful clinical benefits relative to surgical aortic valve replacement (SAVR) in high risk patients with incremental costs considered acceptable ...

HRQoL outcomes not improving for transapical TAVR

June 17, 2015
(HealthDay)—Health-related quality of life (HRQoL) outcomes have not improved for patients undergoing transapical transcatheter aortic valve replacement (TA-TAVR), according to research published online June 9 in Circulation: ...

Results of the PARTNER Trial Cohort A cost effectiveness analysis reported

November 10, 2011
The cost effectiveness of transcatheter aortic valve implantation (TAVR) compared to surgical aortic valve replacement (SAVR) depends on whether TAVR is performed via the femoral artery or transapically, through a small incision ...

Model developed to help predict risk of in-hospital death after TAVR

March 9, 2016
In a study published online by JAMA Cardiology, Fred H. Edwards, M.D., of the University of Florida College of Medicine-Jacksonville, and colleagues developed a statistical model to predict risk of in-hospital death after ...

One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement

July 12, 2016
Overall one-year survival was over 85 percent for high-risk or inoperable patients who underwent aortic valve replacement with the SAPIEN 3 trans-catheter aortic valve replacement system, according to a study published in ...

Recommended for you

Eating yogurt may reduce cardiovascular disease risk

February 15, 2018
A new study in the American Journal of Hypertension, published by Oxford University Press, suggests that higher yogurt intake is associated with lower cardiovascular disease risk among hypertensive men and women.

Newly discovered gene may protect against heart disease

February 14, 2018
Scientists have identified a gene that may play a protective role in preventing heart disease. Their research revealed that the gene, called MeXis, acts within key cells inside clogged arteries to help remove excess cholesterol ...

Blood thinners may raise stroke risk in over-65s with kidney disease

February 14, 2018
People over 65 years old may be increasing their stroke risk by taking anticoagulants for an irregular heartbeat if they also have chronic kidney disease, finds a new study led by UCL, St George's, University of London and ...

Cardiac macrophages found to contribute to a currently untreatable type of heart failure

February 14, 2018
A team of Massachusetts General Hospital (MGH) investigators has discovered, for the first time, that the immune cells called macrophages contribute to a type of heart failure for which there currently is no effective treatment. ...

Study maps molecular mechanisms crucial for new approach to heart disease therapy

February 13, 2018
Creating new healthy heart muscle cells within a patient's own ailing heart. This is how scientists hope to reverse heart disease one day. Today, a new study led by UNC-Chapel Hill researchers reveals key molecular details ...

Quality toolkit improves care in Indian hospitals

February 13, 2018
A simple toolkit of checklists, education materials and quality and performance reporting improved the quality of care but not outcomes in hospitals in the south Indian state of Kerala and may have the potential to improve ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.